List of Excipients in Branded Drug AMLODIPINE BESYLATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	AMLODIPINE BESYLATE	amlodipine besylate	59762-2242	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Mylan Pharmaceuticals Inc	AMLODIPINE BESYLATE	amlodipine besylate	59762-2242	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	AMLODIPINE BESYLATE	amlodipine besylate	59762-2242	MAGNESIUM STEARATE

Generic Drugs Containing AMLODIPINE BESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	amlodipine besylate	0143-9959	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	amlodipine besylate	0143-9959	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	amlodipine besylate	0143-9959	SODIUM STARCH GLYCOLATE TYPE B POTATO

What are the Most Frequently-Used Excipients in AMLODIPINE BESYLATE?

# Of NDCs	Excipient
138	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
12	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
230	CELLULOSE, MICROCRYSTALLINE

Amlodipine Besylate Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Amlodipine besylate is a mature, low-cost calcium-channel blocker with broad generic availability. The main commercial opportunities are not basic immediate-release tablets, which face intense price competition, but differentiated products using excipient engineering, fixed-dose combinations, orally disintegrating delivery, pediatric formats, adherence-focused packaging, and geographically targeted supply strategies.

Amlodipine has low aqueous solubility, high permeability, a long elimination half-life, and a wide therapeutic window. These properties make excipient selection important for dissolution, content uniformity, tablet robustness, stability, and patient usability. The strongest development strategy is usually a conventional immediate-release tablet with controlled particle size, robust wet or dry granulation, and carefully selected disintegrant and lubricant systems.

What is the regulatory and commercial status of amlodipine besylate?

Amlodipine besylate is the besylate salt of amlodipine, an orally active dihydropyridine calcium-channel blocker approved for hypertension and coronary artery disease-related indications. In the United States, marketed strengths generally include 2.5 mg, 5 mg, and 10 mg amlodipine-equivalent tablets.

Attribute	Amlodipine besylate
Drug class	Dihydropyridine calcium-channel blocker
Primary indications	Hypertension; chronic stable or vasospastic angina; coronary artery disease
Common strengths	2.5 mg, 5 mg, 10 mg
Typical administration	Once daily
Approximate terminal half-life	30-50 hours
Salt form	Besylate
Development category	Small-molecule generic
Biosimilar pathway	Not applicable
Main FDA pathway for conventional generics	Abbreviated New Drug Application
Main commercial constraint	Low price and high generic competition

Amlodipine besylate is not a biologic and therefore has no biosimilar exposure. Competition comes from abbreviated new drug applications, branded generics, fixed-dose combinations, and products approved outside the United States through national or regional generic pathways.

The original branded product, Norvasc, lost effective small-molecule market exclusivity years ago. Current developers generally compete through manufacturing economics, supply reliability, formulation differentiation, combination products, and market access rather than through protection of the original active ingredient.

What excipients are used in amlodipine besylate tablets?

The reference immediate-release tablet uses conventional pharmaceutical excipients. The Norvasc label identifies microcrystalline cellulose, dibasic calcium phosphate, sodium starch glycolate, and magnesium stearate among the inactive ingredients, with tablet coatings and colorants varying by strength and presentation [1].

Excipient function	Common candidates	Role in an amlodipine tablet
Diluent	Microcrystalline cellulose	Improves tablet mass, compactability, and content uniformity
Mineral diluent	Dibasic calcium phosphate	Adds density and improves compression
Disintegrant	Sodium starch glycolate	Promotes tablet breakup after administration
Alternative disintegrant	Crospovidone or croscarmellose sodium	Can improve rapid disintegration and processing flexibility
Binder	Povidone, copovidone, pregelatinized starch	Supports granule strength and reduces friability
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces punch and die adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces segregation
Wetting aid	Polysorbate or surfactant systems	May improve dissolution, but can create stability and sensory issues
Film former	Hypromellose	Provides protection, color, and swallowability
Plasticizer	Polyethylene glycol or triethyl citrate	Improves film flexibility
Opacifier	Titanium dioxide or approved alternatives	Controls appearance and light transmission

A conventional platform can use microcrystalline cellulose with dibasic calcium phosphate, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate. The formulation should be designed around low-dose content uniformity because the 2.5 mg strength contains a relatively small quantity of active pharmaceutical ingredient.

How does amlodipine solubility affect excipient selection?

Amlodipine is a weak base with pH-dependent solubility. Its solubility is higher in an acidic environment and lower as pH increases. The besylate salt improves handling and pharmaceutical suitability, but it does not eliminate the need for dissolution control.

Excipient selection should address four technical risks:

1. Inadequate dissolution at higher intestinal pH.
2. Segregation caused by low drug loading.
3. Excessive hydrophobicity from over-lubrication.
4. Moisture- or light-related degradation during processing and storage.

The formulation target is rapid, reproducible release under compendial conditions without creating an overly complex product. High-shear wet granulation can improve content uniformity and flow when the active is poorly distributed through the blend. Direct compression is commercially attractive, but it requires tight control of particle-size distribution, bulk density, blend uniformity, and lubricant exposure.

Which excipients improve dissolution?

Superdisintegrants are usually the first formulation lever. Crospovidone can produce rapid water uptake and tablet breakup without substantial gelling. Croscarmellose sodium provides swelling and wicking. Sodium starch glycolate provides strong swelling but can be sensitive to excessive compression and formulation moisture.

Surfactants can improve wetting, but their use should be justified by dissolution data. They may increase hygroscopicity, alter tablet hardness, create taste issues in orally disintegrating products, or complicate stability. Particle-size reduction, controlled granulation, and salt-form control may provide a lower-risk route than adding a surfactant.

Magnesium stearate should be optimized rather than maximized. Excessive concentration or prolonged blending can create a hydrophobic tablet surface and slow dissolution. Sodium stearyl fumarate can be considered when lubrication is limiting dissolution, although its compatibility, cost, and regulatory acceptability must be assessed for the target market.

What is the best excipient platform for a standard generic tablet?

The most commercially practical platform is a low-complexity immediate-release tablet.

Recommended development architecture

A typical starting design may include:

• Microcrystalline cellulose or a cellulose-phosphate blend as the principal diluent.
• Dibasic calcium phosphate where higher density and improved compression are needed.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as the primary disintegrant.
• Colloidal silicon dioxide as a flow aid.
• Magnesium stearate or sodium stearyl fumarate as lubricant.
• Hypromellose film coating for product identification and swallowability.

The exact percentages should be established through design-of-experiments work rather than copied from a reference label. Critical material attributes include active particle size, polymorphic or solid-state form, excipient moisture, lubricant specific surface area, and granule particle-size distribution.

Direct compression versus wet granulation

Development factor	Direct compression	Wet granulation
Capital cost	Lower	Higher
Process complexity	Lower	Higher
Content uniformity risk	Higher at low drug loading	Generally lower if granulation is controlled
Moisture exposure	Lower	Higher
Flow improvement	Moderate	Strong
Scale-up burden	Lower	Higher
Best use case	Free-flowing, uniform active blend	Poor flow or segregation-prone active

Direct compression is attractive for high-volume generic supply because it reduces unit operations and energy consumption. Wet granulation can be preferable for the 2.5 mg strength or for active material with poor flow and broad particle-size distribution.

What formulations are protected or commercially differentiated?

Conventional amlodipine besylate tablets have limited opportunity for meaningful exclusivity because the active ingredient and basic dosage form are long established. Differentiation is more plausible in the following formats:

Orally disintegrating tablets

An orally disintegrating tablet can target patients with dysphagia, older adults, and patients who have difficulty swallowing conventional tablets. Crospovidone, mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and taste-masking systems may be relevant.

The principal risks are bitter taste, friability, moisture sensitivity, and packaging cost. Unit-dose blister packaging is often more suitable than multidose bottles.

Pediatric liquid or suspension products

Amlodipine is widely used in pediatric hypertension, although formulations and labeling vary by jurisdiction. A liquid product can improve dose flexibility and administration for children. Key excipient issues include:

• pH control and chemical stability.
• Suspending-agent selection.
• Preservative effectiveness.
• Dose uniformity after shaking.
• Palatability.
• Compatibility with dosing syringes.
• Microbial control.

Potential vehicles include aqueous suspensions, oral solutions where solubility permits, and powder-for-reconstitution systems. Pediatric excipient selection requires particular attention to ethanol, propylene glycol, parabens, benzoates, sorbitol, and other excipients that may create age-specific safety or tolerability concerns. FDA and EMA guidance should be applied to the target population [2,3].

Fixed-dose combinations

The strongest commercial opportunity is often a combination product rather than amlodipine monotherapy. Established combinations include amlodipine with:

• Angiotensin-converting enzyme inhibitors.
• Angiotensin II receptor blockers.
• Thiazide or thiazide-like diuretics.
• Beta blockers.
• Statins in cardiovascular-risk products.

Combination tablets can reduce pill burden and improve adherence. Their development is technically harder because each active may have different dose, solubility, compression, stability, and dissolution requirements.

Amlodipine combinations with valsartan, olmesartan, telmisartan, losartan, and benazepril illustrate the commercial logic of pairing a calcium-channel blocker with a renin-angiotensin system agent. The opportunity is strongest in markets where hypertension treatment guidelines favor combination therapy and where branded combination products remain expensive.

Modified-release systems

Amlodipine already has once-daily dosing and a long half-life. Modified release therefore has limited clinical value compared with immediate-release tablets. A controlled-release product would face a high burden of proof and may not justify formulation and regulatory costs unless it solves a specific tolerability, adherence, or combination-product problem.

How strong is the patent estate for amlodipine besylate?

The core active-ingredient and conventional tablet opportunity is weak from an exclusivity perspective. The original Norvasc patent estate expired, and generic amlodipine products have been available for many years. Current value is more likely to arise from narrow formulation, combination, manufacturing, or packaging claims than from broad claims covering amlodipine besylate itself.

IP category	Commercial relevance
Amlodipine active ingredient	Low; mature and widely genericized
Besylate salt	Low for broad protection; salt-specific claims require careful prior-art analysis
Immediate-release tablet	Low unless a narrowly defined formulation has an enforceable claim
Orally disintegrating product	Moderate if taste masking, excipient ratios, or performance are distinctive
Pediatric liquid	Moderate where stability, suspension, or dosing technology is novel
Fixed-dose combination	Moderate to high depending on active pair and jurisdiction
Manufacturing process	Moderate if it materially improves impurity profile, yield, or scale-up
Packaging and adherence system	Usually low for drug exclusivity, but commercially useful
Device-linked delivery	Limited for standard oral tablets

A current freedom-to-operate review should examine U.S. patents, international filings, national-phase status, terminal disclaimers, PTA or PTE adjustments, and claim scope. The FDA Orange Book remains the primary source for listed patents and regulatory exclusivity associated with approved drug products [4].

When does amlodipine lose exclusivity and what is the Paragraph IV risk?

Amlodipine’s original U.S. small-molecule exclusivity has already expired. A conventional generic developer therefore does not normally face the same launch barrier that applies to a recently approved branded drug.

Paragraph IV litigation remains relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a mature amlodipine product, the principal risks are:

• A later-listed formulation or combination patent.
• A patent covering a specific dosage form.
• A patent attached to a combination product rather than amlodipine monotherapy.
• A patent covering a manufacturing route or solid form.
• A patent listed for a branded product with a different active ingredient combination.

The 30-month stay mechanism under the Hatch-Waxman framework can delay approval when the brand sponsor timely files patent litigation after receiving a Paragraph IV notice [5]. For basic amlodipine tablets, the commercial significance of Paragraph IV activity is generally lower than for newer cardiovascular products because multiple generic suppliers already compete.

What is the FDA regulatory status of amlodipine generic products?

A conventional amlodipine besylate tablet is generally developed through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant must address:

• Same active ingredient and strength.
• Same dosage form and route.
• Pharmaceutical equivalence.
• Bioequivalence.
• Impurity and degradation-product control.
• Dissolution similarity.
• Manufacturing process validation.
• Stability under ICH conditions.
• Labeling consistency.

The product should be evaluated against the applicable USP monograph and FDA product-specific guidance where available. FDA’s Dissolution Methods Database and ANDA guidance provide relevant development and submission tools [6,7].

A novel excipient can raise development risk. Using established compendial excipients at conventional levels generally reduces regulatory friction. A new excipient or an unusual route of administration may require additional safety justification and can remove the product from a straightforward generic pathway.

Which companies are challenging the amlodipine market?

The market is supplied by numerous multinational and regional generic manufacturers, contract development and manufacturing organizations, and branded-generic companies. Competition is typically based on:

• Lowest landed cost.
• Reliable active pharmaceutical ingredient supply.
• Regulatory inspection history.
• Product availability.
• Private-label and health-system contracts.
• Packaging configurations.
• Fixed-dose combination breadth.

The relevant competitive set differs by jurisdiction. In the United States, retail and mail-order channels favor scale, automated packaging, and supply continuity. In emerging markets, hospital tenders and distributor relationships may matter more than formulation differentiation.

Because the product is mature, a new entrant needs a cost or access advantage. A second or third conventional tablet with no manufacturing distinction is unlikely to earn premium pricing.

What manufacturing and excipient barriers affect commercial success?

The active dose is low, particularly at 2.5 mg, so blend uniformity is a central manufacturing issue. Important process controls include:

• Active particle-size distribution.
• Premixing and geometric dilution.
• Blend sampling strategy.
• Granulation endpoint.
• Compression-force control.
• Lubrication time.
• Tablet weight and content uniformity.
• Dissolution across tablet hardness ranges.
• Coating weight gain.
• Packaging moisture protection.

Amlodipine besylate can be exposed to light, heat, and moisture during processing and storage. Stability programs should monitor assay, degradation products, dissolution, appearance, and mechanical properties. Light-protective packaging may be justified where the formulation or market distribution chain creates elevated exposure.

The strongest manufacturing IP opportunity lies in impurity control, continuous processing, high-throughput low-dose blending, and robust combination-tablet manufacturing. Process claims are valuable only if they are difficult to design around and produce measurable cost, quality, or yield benefits.

How large is the commercial opportunity?

Amlodipine is a high-volume cardiovascular generic, but the base product is heavily commoditized. Revenue exposure depends on volume and channel rather than high unit price.

Opportunity	Margin potential	Development complexity	Commercial attractiveness
Standard 5 mg and 10 mg tablets	Low	Low	Scale-dependent
2.5 mg tablet	Low to moderate	Moderate	Useful for titration and pediatric dosing
Orally disintegrating tablet	Moderate	Moderate	Niche and adherence-focused
Pediatric liquid	Moderate	Moderate to high	Attractive where pediatric supply is limited
Fixed-dose combination	Moderate to high	High	Strongest differentiated opportunity
Contract manufacturing	Low to moderate	Moderate	Depends on utilization and compliance record
Emerging-market private label	Low to moderate	Low to moderate	Volume opportunity with price pressure
Modified-release product	Uncertain	High	Usually weak risk-adjusted case

The clearest commercial thesis is a differentiated combination product supported by reliable supply and a regulatory strategy aligned with the target market. A standalone immediate-release tablet can still be viable when the developer has low-cost manufacturing, an approved source of active ingredient, and access to large-volume tenders.

How should a commercial excipient strategy be structured?

A practical strategy has three tiers.

Tier one: low-risk generic platform

Use established excipients, a conventional immediate-release tablet, standard film coating, and a robust direct-compression or wet-granulation process. This platform supports rapid development and broad regulatory acceptability.

Tier two: targeted patient-use differentiation

Develop an orally disintegrating tablet, pediatric suspension, or small-dose presentation. The value proposition should be tied to adherence, swallowing difficulty, pediatric dosing, or supply gaps.

Tier three: combination and lifecycle products

Use amlodipine as one component of a fixed-dose cardiovascular regimen. Protect the product through formulation know-how, manufacturing process control, regulatory exclusivity where available, and brand or channel access. Patent protection may be narrower than for a new molecular entity, so the commercial plan should not depend solely on patent enforcement.

Key Takeaways

• Amlodipine besylate is a mature, widely genericized small molecule with no biosimilar risk.
• Conventional tablets use well-established excipients such as microcrystalline cellulose, dibasic calcium phosphate, sodium starch glycolate, and magnesium stearate.
• Low-dose content uniformity, dissolution, lubrication, and moisture control are the main formulation challenges.
• Direct compression offers the lowest-cost platform; wet granulation can improve flow and content uniformity.
• Orally disintegrating tablets and pediatric liquids provide targeted differentiation but require taste, moisture, stability, and packaging work.
• Fixed-dose combinations offer the strongest commercial opportunity because they reduce pill burden and can command better channel access.
• The original core patent and exclusivity barriers have expired; current IP value is concentrated in formulation, combination, process, and manufacturing claims.
• A conventional new entrant needs a cost, supply, tender, or distribution advantage to compete effectively.
• The most defensible strategy combines established excipients, low-complexity manufacturing, reliable supply, and a differentiated cardiovascular combination.

Frequently Asked Questions

Is amlodipine besylate a BCS Class II drug?

Amlodipine is generally treated as a low-solubility, high-permeability compound for formulation purposes. Its pH-dependent solubility makes dissolution and particle-size control important, even though the product is administered at a low dose.

Which excipient is best for amlodipine tablet disintegration?

Crospovidone, croscarmellose sodium, and sodium starch glycolate are credible candidates. The best choice depends on tablet hardness, granulation method, moisture exposure, dissolution target, and compatibility with the selected diluent system.

Can amlodipine besylate be developed as an oral liquid?

Yes. An oral liquid or suspension can support pediatric dosing and patients who cannot swallow tablets. The principal development issues are chemical stability, dose uniformity, microbial control, preservative selection, and palatability.

Does amlodipine besylate have active biosimilar competition?

No. Amlodipine besylate is a small molecule. Competition occurs through generic drug applications rather than biosimilar applications.

Are formulation patents still commercially important for amlodipine?

They can be important for specific products, particularly fixed-dose combinations, orally disintegrating tablets, pediatric formulations, and manufacturing processes. Broad protection for conventional amlodipine tablets is weak because the product has been generic for many years.

References

1. Pfizer Laboratories. (2023). Norvasc (amlodipine besylate) tablets: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2016). General principles for evaluating the abuse deterrence of generic solid oral opioid drug products. FDA.

3. European Medicines Agency. (2013). Guideline on pharmaceutical development of medicines for paediatric use. EMA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

6. U.S. Food and Drug Administration. (2024). Dissolution methods database. FDA.

7. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format. FDA.